(Q35011794)

5 August 2017

1 reference

title

Pharmacotherapy of anxious disorders (English)

1 reference

5 August 2017

0 references

1

Michel Bourin

1 reference

5 August 2017

Olivier Lambert

2

1 reference

5 August 2017

1 December 2002

1 reference

5 August 2017

Human Psychopharmacology

1 reference

5 August 2017

17

1 reference

5 August 2017

8

1 reference

5 August 2017

383-400

1 reference

Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder

5 August 2017

1 reference

MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder

21 January 2018

1 reference

Traumatic events and posttraumatic stress disorder in an urban population of young adults

21 January 2018

1 reference

Psychobiologic mechanisms of posttraumatic stress disorder

21 January 2018

1 reference

Treatment of posttraumatic stress disorder with amitriptyline and placebo.

21 January 2018

1 reference

Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.

21 January 2018

1 reference

Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder

21 January 2018

1 reference

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis

21 January 2018

1 reference

The Eating Attitudes Test: comparative analysis of female and male students at the Public Ballet School of Berlin.

21 January 2018

1 reference

Increased substance use in survivors of the Herald of Free Enterprise disaster

21 January 2018

1 reference

The epidemiology of obsessive-compulsive disorder in five US communities.

21 January 2018

1 reference

Social phobia subtypes in the National Comorbidity Survey.

21 January 2018

1 reference

Posttraumatic stress disorder in the National Comorbidity Survey

21 January 2018

1 reference

Quality of life for patients with obsessive-compulsive disorder.

21 January 2018

1 reference

Selective alteration of personality and social behavior by serotonergic intervention

21 January 2018

1 reference

A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents.

21 January 2018

1 reference

Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey

21 January 2018

1 reference

Quality of life in panic disorder.

21 January 2018

1 reference

Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.

21 January 2018

1 reference

Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder.

21 January 2018

1 reference

Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results

21 January 2018

1 reference

Sertraline in the treatment of panic disorder: a double-blind multicenter trial.

21 January 2018

1 reference

A symptom provocation study of posttraumatic stress disorder using positron emission tomography and script-driven imagery.

21 January 2018

1 reference

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

21 January 2018

1 reference

Social phobia. Comorbidity and morbidity in an epidemiologic sample

21 January 2018

1 reference

Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine

21 January 2018

1 reference

Prospective study of posttraumatic stress disorder and depression following trauma

21 January 2018

1 reference

Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.

21 January 2018

1 reference

Obsessive-compulsive disorder in the community: an epidemiologic survey with clinical reappraisal

21 January 2018

1 reference

Lactic acid response to caffeine in panic disorder: comparison with social phobics and normal controls.

21 January 2018

1 reference

The cross-national epidemiology of panic disorder

21 January 2018

1 reference

DSM-III-R generalized anxiety disorder in the National Comorbidity Survey.

21 January 2018

1 reference

Conflict between current knowledge about posttraumatic stress disorder and its original conceptual basis

21 January 2018

1 reference

Is the course of panic disorder the same in women and men?

21 January 2018

1 reference

Increasing identification and referral of panic disorder over the past decade

21 January 2018

1 reference

[123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder

21 January 2018

1 reference

21 January 2018

1 reference

A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder

21 January 2018

1 reference

ECT, research, and professional ambivalence

21 January 2018

1 reference

How psychiatrists can build new therapies for impotence

21 January 2018

1 reference

Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report.

21 January 2018

1 reference

Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group

21 January 2018

1 reference

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder

21 January 2018

1 reference

The Boundary of Social Phobia

21 January 2018

1 reference

Predicting response to amitriptyline in posttraumatic stress disorder

21 January 2018

1 reference

Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder

21 January 2018

1 reference

Treatment of traumatic war neurosis with phenelzine

21 January 2018

1 reference

Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder

21 January 2018

1 reference

Sertraline for social phobia: a double-blind, placebo-controlled crossover study

21 January 2018

1 reference

A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder

21 January 2018

1 reference

A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.

21 January 2018

1 reference

Preliminary study of carbamazepine in post-traumatic stress disorder

21 January 2018

1 reference

Paroxetine in social phobia.

21 January 2018

1 reference

Fluoxetine versus placebo in posttraumatic stress disorder.

21 January 2018

1 reference

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

21 January 2018

1 reference

Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group

21 January 2018

1 reference

Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper

21 January 2018

1 reference

Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder

21 January 2018

1 reference

A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder

21 January 2018

1 reference

Noradrenergic and serotonergic function in posttraumatic stress disorder

21 January 2018

1 reference

Selective serotonin reuptake inhibitors in the treatment of post-traumatic stress disorder: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

Fluoxetine efficacy in social phobia

21 January 2018

1 reference

A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder

21 January 2018

1 reference

The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder

21 January 2018

1 reference

7 January 2021

Lifetime co-morbidity of panic attacks and major depression in a population-based study: age of onset.

1 reference

7 January 2021

Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group

1 reference

7 January 2021

Current treatments of the anxiety disorders in adults

1 reference

7 January 2021

Comorbidity of panic and somatization disorder: a genetic-epidemiological approach

1 reference

7 January 2021

At risk for anxiety: I. Psychopathology in the offspring of anxious parents

1 reference

7 January 2021

Inositol in the treatment of trichotillomania and compulsive skin picking

1 reference

7 January 2021

A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder

1 reference

7 January 2021

Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis

1 reference

7 January 2021

Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial

1 reference

7 January 2021

Posttraumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment

1 reference

7 January 2021

Adrenergic status in anxiety disorders: platelet alpha 2-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and in normal subjects

1 reference

7 January 2021

One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample

1 reference

7 January 2021

Fenfluramine and brain serotonin

1 reference

7 January 2021

Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study

1 reference

7 January 2021

Flumazenil challenge in social phobia

1 reference

7 January 2021

Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators

1 reference

7 January 2021

Maintenance drug therapy of panic disorder

1 reference

7 January 2021

Response characteristics to antidepressants and placebo in post-traumatic stress disorder

1 reference

7 January 2021

Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study

1 reference

7 January 2021

Treatment of social phobia with clonazepam and placebo.

1 reference

7 January 2021

Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder

1 reference

7 January 2021

A Pilot Study of Phenelzine in the Treatment of Post-traumatic Stress Disorder

1 reference

7 January 2021

Fluvoxamine in civilians with posttraumatic stress disorder

1 reference

7 January 2021

5-HT and mechanisms of defence

1 reference

7 January 2021

Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin

1 reference

7 January 2021

The pathogenesis and treatment of obsessive-compulsive disorder

1 reference

7 January 2021

Efficacy of Buspirone in the Treatment of Posttraumatic Stress Disorder: An Open Trial

1 reference

7 January 2021

Psychological and pharmacological treatments of social phobia: a meta-analysis

1 reference

7 January 2021

Analysis of individual symptoms in generalized anxiety--a pooled, multistudy, double-blind evaluation of buspirone

1 reference

7 January 2021

Decreased density of benzodiazepine receptors in lymphocytes of anxious patients: reversal after chronic diazepam treatment.

1 reference

7 January 2021

Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study

1 reference

7 January 2021

Panic disorder and social phobia: effects of comorbidity on familial transmission

1 reference

7 January 2021

Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies

1 reference

7 January 2021

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

1 reference

7 January 2021

The caudate nucleus in obsessive-compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study

1 reference

7 January 2021

Open trial of nefazodone for combat-related posttraumatic stress disorder

1 reference

7 January 2021

Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design

1 reference

7 January 2021

Selective serotonin reuptake inhibitors in post-traumatic stress disorder

1 reference

7 January 2021

Generalized anxiety disorder. An important clinical concern

1 reference

7 January 2021

Studies of a neurochemical link between depression, anxiety, and stress from [3H]imipramine and [3H]paroxetine binding on human platelets

1 reference

7 January 2021

Fenfluramine augmentation of clomipramine treatment of obsessive compulsive disorder.

1 reference

7 January 2021

Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS).

1 reference

7 January 2021

High prevalence of benzodiazepine dependence in out-patient users, based on the DSM-III-R and ICD-10 criteria

1 reference

7 January 2021

Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors

1 reference

7 January 2021

Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials

1 reference

7 January 2021

Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison

1 reference

7 January 2021

Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder

1 reference

7 January 2021

Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine

1 reference

7 January 2021

Sustained urinary norepinephrine and epinephrine elevation in post-traumatic stress disorder.

1 reference

7 January 2021

Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder

1 reference

7 January 2021

Buspirone in the treatment of posttraumatic stress disorder

1 reference

7 January 2021

A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators

1 reference

7 January 2021

Phobic disorders in the elderly

1 reference

7 January 2021

Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder

1 reference

7 January 2021

Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study

1 reference

7 January 2021

Panic disorder and social phobia: possible implications of comorbid depression for drug therapy

1 reference

7 January 2021

Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study

1 reference

7 January 2021

An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder.

1 reference

7 January 2021

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

1 reference

7 January 2021

Physical symptoms in post-traumatic stress disorder.

1 reference

7 January 2021

Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group

1 reference

7 January 2021

Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder

1 reference

7 January 2021

A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group

1 reference

7 January 2021

Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder

1 reference

7 January 2021

Comorbidity in generalized anxiety disorder

1 reference

7 January 2021

Moclobemide in social phobia: a controlled dose-response trial

1 reference

7 January 2021

Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study

1 reference

7 January 2021

Childhood history of anxiety disorders among adults with social phobia: Rates, correlates, and comparisons with patients with panic disorder

1 reference

7 January 2021

An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder.

1 reference

7 January 2021

Discontinuation reactions to alprazolam in panic disorder

1 reference

7 January 2021

Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.

1 reference

7 January 2021

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial

1 reference

7 January 2021

Prevalence of civilian trauma and posttraumatic stress disorder in a representative national sample of women

1 reference

7 January 2021

Long-term Diazepam Therapy and Clinical Outcome

1 reference

7 January 2021

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

1 reference

7 January 2021

Peripheral-type benzodiazepine receptors in anxiety disorders.

1 reference

7 January 2021

Paroxetine efficacy in the treatment of generalized anxiety disorder

1 reference

7 January 2021

Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group

1 reference

7 January 2021

Behavioral inhibition in childhood: a risk factor for anxiety disorders

1 reference

7 January 2021

Fluvoxamine or Placebo in the Treatment of Panic Disorder and Relationship to Blood Concentrations of Fluvoxamine

1 reference

7 January 2021

Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder

1 reference

7 January 2021

Toward establishing procedural, criterion, and discriminant validity for PTSD in early childhood

1 reference

7 January 2021

Two approaches to the diagnosis of posttraumatic stress disorder in infancy and early childhood

1 reference

7 January 2021

Placebo-controlled trial of moclobemide in social phobia

1 reference

7 January 2021

Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects.

1 reference

7 January 2021

Use of benzodiazepines in anxiety disorders

1 reference

7 January 2021

The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies

1 reference

7 January 2021

Imipramine in the treatment of social phobia.

1 reference

7 January 2021

Abnormal dopamine uptake sites in postmortem striatum from patients with tourette's syndrome

1 reference

7 January 2021

Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder

1 reference

7 January 2021

Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation.

1 reference

7 January 2021

Subtypes of social phobia and comorbidity with depression and other anxiety disorders.

1 reference

7 January 2021

Hippocampal volume in women victimized by childhood sexual abuse.

1 reference

7 January 2021

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

1 reference

7 January 2021

Social phobia: an analysis of possible developmental factors.

1 reference

7 January 2021

Comorbid conditions in obsessive-compulsive disorder

1 reference

7 January 2021

Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine

1 reference

7 January 2021

A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder

1 reference

7 January 2021

Pharmacotherapy of Social Phobia

1 reference

7 January 2021

The effect of citalopram in panic disorder

1 reference

7 January 2021

Paroxetine: an update of its use in psychiatric disorders in adults

1 reference

7 January 2021

Spotlight on paroxetine in psychiatric disorders in adults

1 reference

7 January 2021

Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients.

1 reference

7 January 2021

High association of anticardiolipin antibodies with psychosis

1 reference

7 January 2021

The many faces of social anxiety disorder.

1 reference

7 January 2021

Social fears and social phobia in a community sample of adolescents and young adults: prevalence, risk factors and co-morbidity.

1 reference

7 January 2021

Physical dependence on benzodiazepines: differences within the class

1 reference

7 January 2021

Melatonin in medically ill patients with insomnia: a double-blind, placebo-controlled study.

1 reference

7 January 2021

Phenomenology and course of generalised anxiety disorder.

1 reference

7 January 2021

Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder

1 reference

7 January 2021

Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators

1 reference

7 January 2021

Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HUP.435

1 reference

5 August 2017

1 reference

PubMed ID

12457374